SORT BY

FILTER BY

also on other fortune lists

company facts

g500 stats

Global 500

Armando Babani—/EPA-EFE/REX/Shutt ARMANDO BABANI/EPA-EFE/REX/Shutt

276

Merck

MRK

U.S.

The pharmaceutical giant raked in $40.1 billion in global sales in 2017, an increase of 1% from the year before. Merck’s superstar cancer immunotherapy drug Keytruda has continued to be the big performer; it alone brought in $1.46 billion in the first quarter of this year—an increase of 150% from the same time period last year. Success has been a mixed blessing, however. Keytruda now plays an outsize role in Merck’s portfolio, responsible for about 15% of the company’s sales. Moreover, plans to expand the drug’s applications have hit a snag: A collaboration with the biotech research firm Incyte to combine the drug with another experimental therapy was halted.

Looking for leads, investment insights, or competitive intelligence?

CEO

Kenneth C. Frazier

Sector

Health Care

Industry

Pharmaceuticals

HQ Location

Kenilworth, N.J.

Years on Global 500 List

24

Employees

69,000

Key Financials (Last Fiscal Year)
($ Millions)% change
Revenues ($M)$40,1220.8%
Profits ($M)$2,394.0-38.9%
Assets ($M)$87,872
Total Stockholder Equity ($M)$34,336
Profit Ratios
Profit as % of Revenues6.0%
Profits as % of Assets2.7%
Profits as % of Stockholder Equity7.0%
STOCK QUOTE
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Merck

The Health Care Companies Changing the World

Why Merck, Johnson & Johnson, Humana, and others made our crop of firms doing well by doing good.

Read More →
Deploying the Profit Motive to Beat Ebola

An example of the problem-solving powers of business, from Fortune’s Change the World list.

Read More →